Creative Biolabs is experienced in engineering and producing payload delivery bispecific antibodies (BsAbs) products with experimentally verified high-affinity. With experienced experts hammering at Creative Biolabs, we are confident in offering first class BsAbs to meet your project development.
In cancer therapy, radioimmunotherapy refers to the therapy in which an antibody that targets tumor-associated antigen is used to deliver cytotoxic radiation to tumor cells. BsAbs are capable of binding two or more antigens/receptors at the same time or bringing two different targets together. This character makes BsAbs widely used in the payload (drugs, radiolabels or other small molecules) delivery. BsAb-mediated payload delivery is highly specific and sensitive for targets during delivery and is rapidly developed for pretargeting method in radioimmunodetection and radioimmunotherapy.
Though malfunctioning and uncontrolled, tumor cells are still “self” cells. How to target tumor cells over the surrounding tissues is the main obstacle for radioimmunodetection and radioimmunotherapy. High selectivity and specificity guarantee high image resolution in radioimmunodetection, and better efficacy and low toxicity in radioimmunotherapy. Previously, radioactive monoclonal antibodies or antibody fused with radioactive materials were used for such purposes. However, disadvantages of these drugs such as low stability, high immunogenicity, and low affinity for tumor cells limited the efficacy. The long-time and high-dose exposure of normal cells to radiation also leads to high toxicity. An alternative way is the pretargeting method, which separates the localization of tumor (by specific antibody) from the subsequent delivery of the radionuclide. In this method, radiation is not applied until excess free antibodies being cleared from the body.
Figure 1. Schematic diagram of the principal methods for radioimmunotherapy with BsAb pretargeted RIT. (Goldenberg, D. M. 2009)
As an international company, Creative Biolabs is proud to present our integrated and advanced engineering platforms, which ensure budget and time-saving BsAb services for all customers. Our talented and well-trained scientists are here to support your research in academia and pharmaceutics.
1. Goldenberg, D. M. Some like it hot: lymphoma radioimmunotherapy. Blood. 2009, 113(20): 4823-4824.
2. van de Watering, F. C.; et al. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry. Frontiers in medicine. 2014, 1: 44.
3. Sharkey, R. M.; et al. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. In Seminars in nuclear medicine. 2010, 40(3): 190-203.